Biomarkers & Clinical Research

Biography

Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.

Research Interest

Personalised Medicine, biomarkers, genetics